--- title: "Arvinas Q2 2026 earnings: Licensing revenue drives a return to profit" type: "News" locale: "en" url: "https://longbridge.com/en/news/294923137.md" description: "Arvinas reported a return to profitability in Q2 2026, with revenue surging to $249.7 million and diluted EPS reaching $2.58, driven by licensing deals with Pfizer and Rigel, plus a $50 million FDA milestone for VEPPANU. While operating income improved significantly due to reduced R&D costs, cash flow declined as accounting gains did not fully translate to operational cash. The company maintains a cash runway into late 2028 and continues pipeline development." datetime: "2026-08-05T07:02:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294923137.md) - [en](https://longbridge.com/en/news/294923137.md) - [zh-HK](https://longbridge.com/zh-HK/news/294923137.md) --- # Arvinas Q2 2026 earnings: Licensing revenue drives a return to profit Arvinas (Nasdaq: ARVN) reported Q2 2026 revenue of $249.7 million, up from $22.4 million a year earlier, while diluted EPS swung to $2.58 from a loss of $0.84. The turnaround was driven largely by Pfizer collaboration revenue, the Rigel license agreement, and a $50.0 million milestone tied to FDA approval of VEPPANU. Cash, cash equivalents, and marketable securities totaled $567.9 million at June 30, 2026. ## Core financial results Arvinas moved from an operating loss to a profit as revenue increased by $227.3 million and total operating expenses declined by $8.3 million. The expense reduction primarily came from lower R&D spending, partly offset by $9.0 million of new license-revenue costs associated with VEPPANU’s approval and the Rigel agreement. All figures below are GAAP except per-share data. Metric Q2 2026 Q2 2025 Year-over-year change Revenue $249.7M $22.4M Up $227.3M Cost of license revenue $9.0M $0 Up $9.0M R&D expense $52.6M $68.6M Down $16.0M G&A expense $24.0M $25.3M Down $1.3M Total operating expenses $85.6M $93.9M Down $8.3M Operating income (loss) $164.1M $(71.5) M $235.6M improvement Net income (loss) $169.4M $(61.2) M $230.6M improvement Diluted EPS $2.58 $(0.84) $3.42 improvement The $16.0 million reduction in GAAP R&D expense primarily reflected an $11.0 million decline in compensation and related personnel costs and a $3.2 million reduction in external expenses. Lower spending on vepdegestrant was partly offset by increased investment in ARV-806, ARV-027, and ARV-393. GAAP G&A expense declined modestly as lower personnel, infrastructure, and commercial-development costs outweighed a $4.2 million increase in professional fees. On a non-GAAP basis, which excludes restructuring and stock-based compensation, R&D expense fell to $51.4 million from $59.5 million, while G&A expense edged up to $18.4 million from $18.1 million. ## Business and pipeline performance VEPPANU received FDA approval for eligible adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, marking the first FDA approval of a PROTAC therapy. Arvinas and Pfizer subsequently licensed exclusive global development, manufacturing, and commercialization rights to Rigel Pharmaceuticals, and VEPPANU was added to the NCCN breast cancer guidelines as a Category 2A treatment option for the specified patient group. Beyond VEPPANU, Arvinas is preparing several Phase 1 data releases and one new clinical-trial launch. Program Current status Next disclosed milestone ARV-393 Phase 1 dose escalation continues; preliminary activity was observed in early B- and T-cell lymphoma cohorts Early monotherapy data in H2 2026 ARV-102 Evaluated in healthy volunteers and Parkinson’s disease patients Additional biomarker data in October 2026 ARV-027 Single-ascending-dose cohorts completed; multiple-dose enrollment underway Initial muscle AR-degradation data in H1 2027 ARV-6723 Preclinical results showed activity in immune-checkpoint-inhibitor-resistant models Begin Phase 1 enrollment in Q3 2026 ARV-806 Phase 1 dose-escalation enrollment completed Initial monotherapy data in H2 2026; seek an out-licensing agreement for additional trials ARV-393’s reported activity remains preliminary, and the company did not provide response counts or durability data. Arvinas also presented preclinical pan-KRAS degrader results in pancreatic, colorectal, and lung cancer models, but no clinical timeline was disclosed for that program. ## License accounting created profit while cash still declined The revenue increase was concentrated in collaboration and licensing events rather than product sales. Arvinas recognized $112.6 million from its original vepdegestrant collaboration with Pfizer, primarily reflecting recognition of remaining deferred revenue after entering the Rigel agreement. It also recorded $62.5 million from the Rigel license and a $50.0 million development milestone following VEPPANU’s FDA approval. This accounting-driven revenue recognition produced a Q2 profit, but it did not translate dollar-for-dollar into current-period cash. For the first six months of 2026, Arvinas reported $111.8 million of net income while using $114.3 million of cash in operations, with the latter figure net of $35.0 million received under the Rigel agreement. The balance-sheet data show the extent of the cash decline and the company’s limited debt burden. Metric Amount Comparison or basis Cash, cash equivalents, and marketable securities $567.9M $685.4M at Dec. 31, 2025 Six-month decline in cash and securities $117.5M Six months ended June 30, 2026 Cash used in operations $114.3M Six months ended June 30, 2026; net of $35.0M received from Rigel Unrealized losses on marketable securities $2.0M Six months ended June 30, 2026 Lab equipment and leasehold-improvement purchases $1.5M Six months ended June 30, 2026 Long-term debt $0.3M $0.4M at Dec. 31, 2025 ## Financial guidance Based on its current operating plan, Arvinas believes its June 30 cash resources can fund planned operating expenses and capital expenditures into the second half of 2028. The company did not provide revenue or earnings guidance. Metric Latest guidance Cash runway Into the second half of 2028 The runway depends on the current spending plan and therefore remains sensitive to clinical-trial expansion, partnership activity, and the timing of pipeline development. ## Recent insider transactions The supplied insider dataset reports 555,552 shares purchased across 13 transactions and 126,026 shares sold across 18 transactions during the past six months, resulting in net purchases of 429,526 shares. Total insider holdings were listed at 5.1 million shares, with net purchases equal to 9.20% of those holdings; the data do not establish that all reported purchases were open-market transactions. The 10 latest reported entries consisted of six director stock awards and four officer sales. The source did not provide share counts for these individual entries. Date Insider Role Transaction Reported value Jun. 24, 2026 Leslie V. Norwalk Director Stock award at $0.00 per share $0 Jun. 24, 2026 Everett V. Cunningham Director Stock award at $0.00 per share $0 Jun. 24, 2026 Linda C. Bain Director Stock award at $0.00 per share $0 Jun. 24, 2026 Laurie Smaldone Alsup Director Stock award at $0.00 per share $0 Jun. 24, 2026 Briggs W. Morrison, M.D. Director Stock award at $0.00 per share $0 Jun. 24, 2026 Edward Moore Kennedy Jr. Director Stock award at $0.00 per share $0 Jun. 24, 2026 Andrew Saik Chief Financial Officer Sale at $8.16 per share $46,474 Jun. 17, 2026 Angela M. Cacace Officer Sale at $7.60 per share $19,565 May 21, 2026 Randy Teel Chief Executive Officer Sale at $9.04 per share $19,962 May 11, 2026 Noah Berkowitz Officer Sale at $9.94 per share $110,385 ## Risks investors need to watch - **Transaction-driven revenue may remain uneven.** Q2’s profit depended heavily on deferred revenue recognition, licensing income, and an approval milestone, making the quarter less representative of ongoing operating cash generation. - **Commercial execution now depends on Rigel.** Rigel holds exclusive global rights to develop, manufacture, and commercialize VEPPANU, so future product execution depends on the licensee’s performance. - **Upcoming pipeline evidence is still early-stage.** ARV-393 activity was preliminary, while ARV-102, ARV-027, ARV-6723, and ARV-806 remain in Phase 1 or preclinical development. - **Cash consumption remains significant.** Arvinas used $114.3 million in operating cash during the first half despite receiving $35.0 million from Rigel. The projected runway assumes the current operating plan. - **Further ARV-806 development requires a licensing strategy.** Arvinas plans to seek an out-licensing agreement for additional trials beyond the current dose-escalation work. ## Summary Arvinas’ Q2 2026 profit reversal was primarily the result of VEPPANU-related collaboration, licensing, and milestone revenue, supported by lower R&D spending. The next operating tests are Rigel’s execution with the newly approved product, upcoming Phase 1 data across several programs, and whether Arvinas can maintain its planned cash runway while advancing the pipeline. Find out more ### Related Stocks - [ARVN.US](https://longbridge.com/en/quote/ARVN.US.md) - [RIGL.US](https://longbridge.com/en/quote/RIGL.US.md) - [PFE.US](https://longbridge.com/en/quote/PFE.US.md) ## Related News & Research - [Pfizer repels Covid-19 sales tumble to raise 2026 guidance](https://longbridge.com/en/news/294878492.md) - [Arvinas posts corporate presentation highlighting PROTAC degrader pipeline in oncology and neurology](https://longbridge.com/en/news/295231676.md) - [Pfizer extends rally to seventh straight session](https://longbridge.com/en/news/295454569.md) - [Rigel Pharmaceuticals posts corporate deck highlighting VEPPANU in-license and commercial launch plan](https://longbridge.com/en/news/294880787.md) - [BUZZ-Street View: Growth drugs lift Pfizer outlook, but execution remains key](https://longbridge.com/en/news/294968791.md)